Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANTAGE: Standard vs prolonged neoadjuvant chemotherapy in borderline/locally advanced pancreatic cancer
2022-502117-29-00Phase 3Authorised
- Sponsor
- Region Västra Götaland
- Start
- Feb 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of gemcitabine, paclitaxel, irinotecan, oxaliplatin, fluorouracil and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Region Västra Götaland. Primary endpoints: Overall survival at 24 months after randomization (all patients) and Overall survival at 24 months after randomization (resected patients). Planned start Feb 2023; status: authorised.
02
Drugs
gemcitabinepaclitaxelirinotecanoxaliplatinfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2022-502117-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502117-29-00.